Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery : A pilot randomized study
Published by Elsevier Inc..
AIM: We investigated if a dipeptidyl peptidase-4 inhibitor, sitagliptin, can prevent perioperative stress hyperglycemia in patients without prior history of diabetes mellitus undergoing general surgery.
METHODS: This double-blind pilot trial randomized general surgery patients to receive sitagliptin (n = 44) or placebo (n = 36) once daily, starting one day prior to surgery and continued during the hospital stay. The primary outcome was occurrence of stress hyperglycemia, defined by blood glucose (BG) >140 mg/dL and >180 mg/dL after surgery. Secondary outcomes included: length-of-stay, ICU transfers, hypoglycemia, and hospital complications.
RESULTS: BG >140 mg/dL was present in 44 (55%) of subjects following surgery. There were no differences in hyperglycemia between placebo and sitagliptin (56% vs. 55%, p = 0.93). BG >180 mg/dL was observed in 19% and 11% of patients treated with placebo and sitagliptin, respectively, p = 0.36. Both treatment groups had resulted in similar postoperative BG (148.9 ± 29.4 mg/dL vs. 146.9 ± 35.2 mg/dL, p = 0.73). There were no differences in length-of-stay (4 vs. 3 days, p = 0.84), ICU transfer (3% vs. 5%, p = 1.00), hypoglycemia <70 mg/dL (6% vs. 11%, p = 0.45), and complications (14% vs. 18%, p = 0.76).
CONCLUSION: Preoperative treatment with sitagliptin did not prevent stress hyperglycemia or complications in individuals without diabetes undergoing surgery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of diabetes and its complications - 32(2018), 12 vom: 28. Dez., Seite 1091-1096 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fayfman, Maya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.09.2019 Date Revised 08.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jdiacomp.2018.08.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288900030 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288900030 | ||
| 003 | DE-627 | ||
| 005 | 20231225061347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jdiacomp.2018.08.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0962.xml |
| 035 | |a (DE-627)NLM288900030 | ||
| 035 | |a (NLM)30253968 | ||
| 035 | |a (PII)S1056-8727(18)30752-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fayfman, Maya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery |b A pilot randomized study |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2019 | ||
| 500 | |a Date Revised 08.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Inc. | ||
| 520 | |a AIM: We investigated if a dipeptidyl peptidase-4 inhibitor, sitagliptin, can prevent perioperative stress hyperglycemia in patients without prior history of diabetes mellitus undergoing general surgery | ||
| 520 | |a METHODS: This double-blind pilot trial randomized general surgery patients to receive sitagliptin (n = 44) or placebo (n = 36) once daily, starting one day prior to surgery and continued during the hospital stay. The primary outcome was occurrence of stress hyperglycemia, defined by blood glucose (BG) >140 mg/dL and >180 mg/dL after surgery. Secondary outcomes included: length-of-stay, ICU transfers, hypoglycemia, and hospital complications | ||
| 520 | |a RESULTS: BG >140 mg/dL was present in 44 (55%) of subjects following surgery. There were no differences in hyperglycemia between placebo and sitagliptin (56% vs. 55%, p = 0.93). BG >180 mg/dL was observed in 19% and 11% of patients treated with placebo and sitagliptin, respectively, p = 0.36. Both treatment groups had resulted in similar postoperative BG (148.9 ± 29.4 mg/dL vs. 146.9 ± 35.2 mg/dL, p = 0.73). There were no differences in length-of-stay (4 vs. 3 days, p = 0.84), ICU transfer (3% vs. 5%, p = 1.00), hypoglycemia <70 mg/dL (6% vs. 11%, p = 0.45), and complications (14% vs. 18%, p = 0.76) | ||
| 520 | |a CONCLUSION: Preoperative treatment with sitagliptin did not prevent stress hyperglycemia or complications in individuals without diabetes undergoing surgery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a DPP4-inhibitors | |
| 650 | 4 | |a Hospital complications | |
| 650 | 4 | |a Inpatient | |
| 650 | 4 | |a Perioperative management | |
| 650 | 4 | |a Stress hyperglycemia | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
| 650 | 7 | |a Sitagliptin Phosphate |2 NLM | |
| 650 | 7 | |a TS63EW8X6F |2 NLM | |
| 700 | 1 | |a Davis, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Duggan, Elizabeth W |e verfasserin |4 aut | |
| 700 | 1 | |a Urrutia, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Chachkhiani, David |e verfasserin |4 aut | |
| 700 | 1 | |a Schindler, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquel, Francisco J |e verfasserin |4 aut | |
| 700 | 1 | |a Galindo, Rodolfo J |e verfasserin |4 aut | |
| 700 | 1 | |a Vellanki, Priyathama |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes-Umpierrez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Heqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Umpierrez, Guillermo E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes and its complications |d 1997 |g 32(2018), 12 vom: 28. Dez., Seite 1091-1096 |w (DE-627)NLM012632503 |x 1873-460X |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:12 |g day:28 |g month:12 |g pages:1091-1096 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jdiacomp.2018.08.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2018 |e 12 |b 28 |c 12 |h 1091-1096 | ||